ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 6

A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts

Ruby Siegel1 and Salahuddin Ahmed 2, 1Washington State University Spokane, Spokane, WA, 2Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: IL-6R signaling, rheumatoid arthritis, synovium and adhesion molecules

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Cytokines & Cell Trafficking Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interleukin-6 (IL-6) promotes synovial hyperplasia by inducing mediators of adhesion, migration and leukocyte infiltration in rheumatoid arthritis (RA). The extracellular enzymes sulfatase-2 (Sulf-2) and sulfatase-1 (Sulf-1) cleave specific sulfate esters from heparan sulfate proteoglycans (HSPGs) which may affect the receptor/ligand binding and signaling of chemokines, cytokines, and growth factors.  However, the potential role of sulfatases in IL-6 signaling remain unexplored. The present study evaluated the effect of the sulfatases on IL-6 signaling and induction of effector molecules in human RA synovial fibroblasts (RASFs).

Methods: Human RASFs were serum-starved overnight followed by treatment with 100 ng/ml each of IL-6 and IL-6 receptor (IL-6/IL-6R) for different time periods. Conditioned media and whole cell lysates were collected to determine the expression of adhesion (cadherin-11, ICAM-1) and migration (podoplanin) molecules using qRT-PCR and Western blotting. IL-6/IL-6R-induced MCP-1 release in conditioned media was measured by ELISA. Effect of sulfatases on IL-6/IL-6R stimulation was evaluated by small inhibitory RNA (siRNA) knockdown of Sulf-1 and Sulf-2. RASFs treated with siRNA were stimulated with IL-6/IL-6R for 24 hr for protein studies, or for 30 min to determine signaling mechanisms.

Results: Compared to IL-1β (10 ng/ml) or TNF-α (20 ng/ml), IL-6/IL-6R selectively induced the expression of Sulf-2 by 1.5-fold, without marked change in Sulf-1 expression in human RASFs (n=3). In a time-dependent study (n=3; 0-48 hr), IL-6/IL-6R caused a significant increase in the expression of cadherin-11 (2-fold; p< 0.01), podoplanin (2.5-fold; p< 0.05) and ICAM-1 (3.5-fold; p< 0.0001), and the production of MCP-1 in the conditioned media (2.6-fold; p< 0.05). Additionally, IL-6/IL-6R stimulation caused a ~4-fold increase in expression of syndecan-2, a known HSPG target of Sulf-2, in human RASFs (p< 0.01; n=3). Interestingly, densitometric analysis of Western blots showed that knockdown of Sulf-2, but not Sulf-1, preferentially reduced IL-6/IL-6R-induced cadherin-11, podoplanin, and ICAM-1 by 35%, 25%, and 30%, respectively (p< 0.05; n=3). However, siRNA targeted for both Sulf-2 and Sulf-1 proved effective in reducing IL-6/IL-6R-induced MCP-1 production by 35% and 56%, respectively (p< 0.01; n=3). Evaluation of signaling events showed that inhibition of Sulf-2, but not Sulf-1, suppressed IL-6/IL-6R-induced phosphorylation of JAK-1 (Tyr1022) by ~50% while maintaining the expression of SOCS3, a negative regulator of JAK/STAT3 signaling.

Conclusion: Our study identified a novel role of Sulf-2 in facilitating IL-6-induced signaling in RASFs and suggests potential therapeutic value of targeting Sulf-2-dependent pathways in treatment approaches for RA.  


Disclosure: R. Siegel, None; S. Ahmed, None.

To cite this abstract in AMA style:

Siegel R, Ahmed S. A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-novel-role-for-extracellular-sulfatase-2-in-mediating-il-6-induced-adhesion-and-migration-molecules-in-human-rheumatoid-arthritis-synovial-fibroblasts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-role-for-extracellular-sulfatase-2-in-mediating-il-6-induced-adhesion-and-migration-molecules-in-human-rheumatoid-arthritis-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology